Anlon Healthcare IPO: GMP, IPO Price & Key Details
Hello everyone, Get ready for another exciting Mainboard IPO! Anlon Healthcare Limited is all set to open its initial public offering. If you're eyeing new investment opportunities in the chemical and pharmaceutical sector, here's everything you need to know about this upcoming IPO.
About the Company
Anlon Healthcare Limited specializes in the manufacturing of High Purity Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs). These are crucial components used in various pharmaceutical formulations, as well as in nutraceutical, personal care, and veterinary products. Operating from its manufacturing facility in Rajkot, Gujarat, Anlon Healthcare is positioned in a growing segment of the healthcare industry, serving critical needs across different therapeutic areas.
Anlon Healthcare IPO: Key Details
| Particulars | Details |
|---|---|
| IPO Open Date | August 26, 2025 |
| IPO Close Date | August 29, 2025 |
| Price Band | ₹86 - ₹91 per share |
| Lot Size | 164 shares |
| Issue Size | ₹121 Crore (Fresh Issue) |
| Retail Reservation | 10% |
| Market Cap (Post-issue) | ₹483.6 Crore |
| Promoter Holding (Post-issue) | 52.68% |
| Lead Manager | Interactive Financial Services |
Financial Performance
Anlon Healthcare has shown impressive financial growth over the last two fiscal years:
| Particulars (₹ Crore) | FY24 | FY25 |
|---|---|---|
| Revenue | 66.7 | 120.45 |
| Profit After Tax (PAT) | 9.7 | 20.5 |
Latest Grey Market Premium (GMP)
The Grey Market Premium (GMP) offers an unofficial indication of market sentiment before listing. The current GMP for Anlon Healthcare IPO is reported at ₹5. At the upper end of the price band (₹91), this suggests a potential listing at ₹96, which is approximately a 5.5% premium. Keep in mind that GMP is highly speculative and can change rapidly.
Valuation and Peer Comparison
At the upper price band of ₹91, Anlon Healthcare's IPO is valued at a Price-to-Earnings (P/E) ratio of 23.6x based on its FY25 earnings. Let's compare this with some of its listed peers:
- Kronox Lab Sciences: 24.8x
- AMI Organics: 71.5x
- Surpriya Lifesciences: 29.2x
Anlon Healthcare's P/E multiple appears reasonable compared to its industry counterparts, especially considering its recent revenue and PAT growth.
Allotment Chances
The IPO comprises a full fresh issue, with 10% reserved for retail investors. Here’s a breakdown of the lots available for different investor categories:
| Category | Number of Lots |
|---|---|
| Retail Investors | 8,110 |
| Big HNI | 579 |
| Small HNI | 290 |
The actual allotment chances will become clearer once the subscription figures are out. High subscription rates in any category will mean lower chances of allotment for individual applicants in that category.
Frequently Asked Questions (FAQs)
1. What is Anlon Healthcare Limited?
Anlon Healthcare Limited is a chemical manufacturing company specializing in High Purity Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs) for pharmaceutical, nutraceutical, personal care, and veterinary products.
2. What are the Anlon Healthcare IPO dates?
The Anlon Healthcare IPO will open for subscription on August 26, 2025, and close on August 29, 2025.
3. What is the price band and lot size for the Anlon Healthcare IPO?
The price band for the Anlon Healthcare IPO is ₹86 - ₹91 per share, with a lot size of 164 shares.
4. What is the current Grey Market Premium (GMP) for Anlon Healthcare IPO?
The current Grey Market Premium (GMP) for Anlon Healthcare IPO is ₹5, indicating a potential listing at approximately ₹96 per share (5.5% premium over the upper price band).
5. How does Anlon Healthcare's valuation compare to its peers?
At the upper price band, Anlon Healthcare's IPO is valued at a P/E ratio of 23.6x (based on FY25 earnings), which is competitive compared to its listed peers like Kronox Lab Sciences (24.8x), AMI Organics (71.5x), and Surpriya Lifesciences (29.2x).
6. What is the total issue size and promoter holding post-issue?
The IPO size is ₹121 Crore, consisting entirely of a fresh issue. The promoter holding post-issue will be 52.68%.
Anlon Healthcare's IPO looks promising given its robust financial performance, strategic position in the pharmaceutical intermediates market, and a competitive valuation. As with any investment, it’s crucial to review the Red Herring Prospectus (RHP) thoroughly and make an informed decision.